Twitter Facebook LinkedIn

Heat Biologics, Inc. Heat Biologics, Inc.

  • Home
  • About
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Technology
  • Pipeline
    • Overview
    • HS-110
    • HS-130
    • Expanded Access
    • Scientific Publications
  • Investors
  • News & Media
  • Careers
  • Contact

News Releases

Heat Biologics Announces Multiple Presentations on PTX-35 at the Upcoming 3rd Annual Treg Directed Therapies Summit

May 19, 2021

Heat Biologics Appoints Anthony Manning, Ph.D. as Chief Scientific Advisor

May 10, 2021

Heat Biologics Provides First Quarter 2021 Business Update; Reports Continued Progress on Oncology and COVID-19 Vaccine Programs

May 5, 2021

Heat Biologics Announces New Preclinical Data on PTX-35, Demonstrating Decreased Regulatory T-cell (Treg) Activity and Delayed Tumor Progression at American Association for Cancer Research (AACR) Annual Meeting 2021

Apr 12, 2021

Heat Biologics Provides Year-End Business Update

Mar 25, 2021

Heat Biologics to Participate at M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference

Mar 8, 2021

Heat Biologics to Present at 2021 BIO CEO & Investor Digital Conference

Feb 12, 2021

Heat Biologics Announces Positive Interim Survival Data from Ongoing HS-110 Phase 2 Non-Small Cell Lung Cancer Trial

Feb 9, 2021

Heat Biologics Announces Publication of Additional Preclinical COVID-19 Vaccine Results

Jan 27, 2021

Heat Biologics CEO to Participate in a Fireside Chat at the B. Riley Securities Oncology Investor Conference on Jan 21, 2021

Jan 20, 2021
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • ...29
    NightHawk Biosciences

    OUR ECOSYSTEM

    SkunkWorx Bio
    Heat Biologics
    Elusys Therapeutics Inc.
    Pelican Therapeutics
    Scorpion Biological Services
    © 2022 Heat Biologics, Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap LinkedIn